Latest News

Helena Noguera Nuñez, MD, discusses a prospective study of the TECNIS Odyssey IOL from ESCRS 2026.

Epithelial basement membrane dystrophy can affect premium IOL outcomes.

EyeCon is an opportunity for ophthalmologists and optometrists to sit down together.

Topline data from the phase 2/3 study show that both dose levels of the subretinal gene therapy produced significant gains in low luminance visual acuity versus untreated control at 12 months.

Learn who benefits most from Encelto for MacTel type 2, its long-lasting CNTF implant results, and key safety counseling points.

Sessions at the 1-4 October Vienna congress address GA patient selection, AI-based functional prediction, imaging biomarkers, and surgical intervention.

NESTS survey reveals patients often normalize dry eye symptoms, delaying care despite major impacts on daily life.

The 26th EURETINA Congress convenes in Vienna, Austria, from October 1–4, headlined by a new World Retina networking initiative and a revamped Free Paper Forum stage.

RCA's first State of Retina Care report surveys 115+ affiliated specialists on access, practice pressures, and clinical research.

The first patients were dosed in the global phase 3 ORBIT trial evaluating linsitinib as an oral therapy for thyroid eye disease.

Q3 2026 delivered advances in some closely watched pipeline products.

After four years and 500+ office-based procedures, Johnathan Feistmann, MD, shares how the model shortened time to surgery for fovea-threatening cases while reshaping patient experience and practice workflow.

Atrial fibrillation appears to cause thinning of the macular ganglion cell and inner plexiform layer.